This study investigates metastatic KRAS G12D-mutated pancreatic adenocarcinoma. It evaluates the use of an investigational medication combined with chemotherapy.
The study focuses on assessing the effectiveness and safety of this combination compared to a placebo with chemotherapy. It evaluates progression-free survival and overall survival.
- Who can participate: Adults 18 years or older with confirmed metastatic pancreatic cancer with the specific gene mutation can participate. Key eligibility includes good organ function and ability to take oral medications.
- Study details: Participants will receive either the investigational medication with chemotherapy or a placebo with chemotherapy. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand